Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fecal microbiota transplantation (Sheba Medical Center)
- Development stage
- Unknown
- Lead developer
- Sheba Medical Center
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Fecal microbiota transplantation (FMT) is a microbial therapy developed by Sheba Medical Center for the treatment of steroid-resistant or steroid-dependent gut acute graft-versus-host disease (aGVHD). The intervention consists of oral capsules containing frozen fecal microbiota harvested from healthy, unrelated donors. The therapeutic rationale is based on the observation that allogeneic hematopoietic stem cell transplantation (HSCT) causes significant perturbations in the intestinal microbiome (dysbiosis), which are linked to the pathogenesis of aGVHD. By reintroducing a diverse community of commensal microorganisms, FMT aims to restore gut homeostasis and modulate the immune-mediated inflammatory response characteristic of GVHD. This specific formulation is being evaluated in a Phase 1 pilot study to assess its safety and feasibility in adult HSCT recipients.
- Other names
- Fecal Microbiota TransplantationFecal microbiota capsulesFecal microbiota-Sheba Medical Center-acute graft versus host disease
Beyond the preview
Go deeper on Fecal microbiota transplantation (Sheba Medical Center).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fecal microbiota transplantation (Sheba Medical Center).